vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Nexalin Technology, Inc. (NXL). Click either name above to swap in a different company.
Nexalin Technology, Inc. is the larger business by last-quarter revenue ($171.9K vs $169.0K, roughly 1.0× Aligos Therapeutics, Inc.). On growth, Nexalin Technology, Inc. posted the faster year-over-year revenue change (532.5% vs -72.1%). Over the past eight quarters, Nexalin Technology, Inc.'s revenue compounded faster (47.8% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Nexalin Technology, Inc. is a medical technology enterprise that develops and commercializes non-invasive cranial electrotherapy stimulation devices, which help treat mental health conditions including anxiety, depression and insomnia. Its products are mainly sold to healthcare providers and patients in North America and global emerging markets.
ALGS vs NXL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $171.9K |
| Net Profit | — | $-2.4M |
| Gross Margin | — | 87.8% |
| Operating Margin | — | -1403.9% |
| Net Margin | — | -1382.6% |
| Revenue YoY | -72.1% | 532.5% |
| Net Profit YoY | 75.8% | 16.1% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $171.9K | ||
| Q3 25 | $741.0K | $18.1K | ||
| Q2 25 | $965.0K | $70.6K | ||
| Q1 25 | $311.0K | $41.0K | ||
| Q4 24 | $606.0K | $27.2K | ||
| Q3 24 | $1.3M | $36.0K | ||
| Q2 24 | $1.1M | $26.8K | ||
| Q1 24 | $694.0K | $78.7K |
| Q4 25 | — | $-2.4M | ||
| Q3 25 | $-31.5M | $-2.3M | ||
| Q2 25 | $-15.9M | $-1.6M | ||
| Q1 25 | $43.1M | $-2.0M | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | $-2.4M | ||
| Q2 24 | $5.1M | $-1.3M | ||
| Q1 24 | $-34.9M | $-1.0M |
| Q4 25 | — | 87.8% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 66.9% | ||
| Q4 24 | — | 72.4% | ||
| Q3 24 | — | 64.8% | ||
| Q2 24 | — | 73.0% | ||
| Q1 24 | — | 88.4% |
| Q4 25 | — | -1403.9% | ||
| Q3 25 | -3827.4% | -12924.3% | ||
| Q2 25 | -1924.0% | -2296.2% | ||
| Q1 25 | -6187.5% | -4903.6% | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | -6962.1% | ||
| Q2 24 | -2489.5% | -4832.4% | ||
| Q1 24 | -3176.7% | -1364.8% |
| Q4 25 | — | -1382.6% | ||
| Q3 25 | -4256.0% | -12542.3% | ||
| Q2 25 | -1643.8% | -2239.7% | ||
| Q1 25 | 13854.7% | -4847.8% | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | -6794.9% | ||
| Q2 24 | 477.0% | -4785.7% | ||
| Q1 24 | -5023.5% | -1323.4% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | $-3.04 | $-0.13 | ||
| Q2 25 | $-1.53 | $-0.10 | ||
| Q1 25 | $-2.11 | $-0.15 | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | $-0.23 | ||
| Q2 24 | $0.81 | $-0.17 | ||
| Q1 24 | $-5.58 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $3.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $3.7M |
| Total Assets | $88.5M | $4.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $3.7M | ||
| Q3 25 | $99.1M | $4.4M | ||
| Q2 25 | $122.9M | $5.8M | ||
| Q1 25 | $137.9M | $2.1M | ||
| Q4 24 | $56.9M | $3.5M | ||
| Q3 24 | $74.9M | $4.6M | ||
| Q2 24 | $94.5M | $848.8K | ||
| Q1 24 | $112.7M | $2.1M |
| Q4 25 | $53.5M | $3.7M | ||
| Q3 25 | $71.8M | $4.8M | ||
| Q2 25 | $101.9M | $6.0M | ||
| Q1 25 | $116.4M | $2.3M | ||
| Q4 24 | $-29.0M | $3.7M | ||
| Q3 24 | $50.1M | $5.0M | ||
| Q2 24 | $67.2M | $1.4M | ||
| Q1 24 | $59.8M | $2.3M |
| Q4 25 | $88.5M | $4.6M | ||
| Q3 25 | $109.8M | $5.1M | ||
| Q2 25 | $134.7M | $6.6M | ||
| Q1 25 | $150.7M | $2.9M | ||
| Q4 24 | $70.1M | $4.2M | ||
| Q3 24 | $88.4M | $5.3M | ||
| Q2 24 | $108.8M | $1.6M | ||
| Q1 24 | $127.9M | $2.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-1.1M | ||
| Q3 25 | $-24.3M | $-1.5M | ||
| Q2 25 | $-15.5M | $-917.2K | ||
| Q1 25 | $-20.9M | $-1.4M | ||
| Q4 24 | $-18.4M | $-3.9M | ||
| Q3 24 | $-20.1M | $-800.2K | ||
| Q2 24 | $-19.5M | $-1.2M | ||
| Q1 24 | $-22.7M | $-763.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
